CRIS Current Research Information System

BACCARANI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.181
EU - Europa 17.639
AS - Asia 9.129
AF - Africa 1.118
Continente sconosciuto - Info sul continente non disponibili 73
SA - Sud America 50
OC - Oceania 22
Totale 53.212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.102
GB - Regno Unito 5.791
CN - Cina 3.336
SE - Svezia 3.090
VN - Vietnam 2.219
DE - Germania 2.180
IT - Italia 2.039
SG - Singapore 1.843
UA - Ucraina 1.021
IN - India 992
IE - Irlanda 717
FR - Francia 716
RU - Federazione Russa 645
ZA - Sudafrica 406
EE - Estonia 391
TG - Togo 370
CH - Svizzera 267
JP - Giappone 205
JO - Giordania 197
BG - Bulgaria 170
CI - Costa d'Avorio 137
FI - Finlandia 127
BE - Belgio 113
NG - Nigeria 107
IR - Iran 92
GR - Grecia 84
SC - Seychelles 78
CA - Canada 74
HR - Croazia 73
EU - Europa 66
TR - Turchia 55
NL - Olanda 46
AT - Austria 38
LB - Libano 31
PL - Polonia 31
ID - Indonesia 27
BR - Brasile 25
RO - Romania 22
HK - Hong Kong 20
MY - Malesia 20
CZ - Repubblica Ceca 19
AU - Australia 18
ES - Italia 18
KR - Corea 18
UZ - Uzbekistan 18
CL - Cile 13
TW - Taiwan 11
IL - Israele 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BD - Bangladesh 7
PH - Filippine 7
AR - Argentina 6
EG - Egitto 6
PT - Portogallo 6
RS - Serbia 6
TN - Tunisia 6
LT - Lituania 5
AE - Emirati Arabi Uniti 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
QA - Qatar 4
SA - Arabia Saudita 4
AL - Albania 3
DK - Danimarca 3
IQ - Iraq 3
KE - Kenya 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
EC - Ecuador 2
HU - Ungheria 2
KG - Kirghizistan 2
MK - Macedonia 2
ML - Mali 2
MX - Messico 2
PE - Perù 2
PK - Pakistan 2
UG - Uganda 2
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
PA - Panama 1
SI - Slovenia 1
TH - Thailandia 1
Totale 53.212
Salva come PNG Salva come JPEG
Città #
Southend 5.272
Fairfield 3.338
Chandler 2.428
Ashburn 1.997
Woodbridge 1.752
Singapore 1.601
Houston 1.563
Seattle 1.549
Wilmington 1.533
Dong Ket 1.340
Cambridge 1.206
Ann Arbor 1.200
Princeton 1.075
Dublin 712
Boardman 641
Jacksonville 629
Santa Clara 548
Nanjing 528
Westminster 470
Padova 460
Lomé 370
Beijing 368
Bologna 292
Berlin 267
Jinan 242
Saint Petersburg 237
New York 232
Bern 219
Shenyang 219
San Diego 198
Turin 198
Amman 197
Sofia 170
Bremen 167
Hebei 166
Nanchang 158
Tokyo 153
Changsha 150
Abidjan 137
Medford 132
Milan 123
Helsinki 122
Jiaxing 116
Mülheim 111
Redmond 107
Abeokuta 106
Brussels 106
Tianjin 106
Florence 100
Redwood City 98
Zhengzhou 90
Falls Church 87
Norwalk 80
Guangzhou 73
Haikou 73
Mahé 72
Hangzhou 71
Los Angeles 70
Des Moines 65
Dearborn 64
Ningbo 56
Taizhou 55
Taiyuan 50
Shanghai 49
Verona 49
Olalla 48
Toronto 45
Rome 44
Istanbul 41
Lanzhou 40
Kunming 37
London 37
Mountain View 35
Bühl 34
Andover 33
Zanjan 32
Washington 31
Fuzhou 29
Wuhan 29
Leawood 28
Paris 28
Frankfurt am Main 26
Hyderabad 24
Jakarta 23
Vienna 22
Harbin 21
Chengdu 20
Sacramento 19
San Venanzo 18
São Paulo 18
Lausanne 17
Pune 17
Shenzhen 17
Chicago 16
Kuala Lumpur 16
Phoenix 16
San Francisco 16
Frankfurt Am Main 15
Groningen 15
Monmouth Junction 15
Totale 37.135
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 333
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 275
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 254
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 253
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 237
18F-FDG PET early after radiotherapy in lymphoma patients. 236
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 226
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 217
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 216
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 216
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 204
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 204
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 199
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 198
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 195
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 195
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 191
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 188
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 187
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 183
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 181
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 181
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 180
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 180
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 175
Advances in the treatment for haematological malignancies. 174
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 173
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 173
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 173
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 172
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 171
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 170
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 169
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 167
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 167
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 165
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 165
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 164
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 163
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 163
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 162
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 161
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 161
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 161
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 160
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 158
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. 157
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 157
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 156
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 155
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 154
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 153
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 153
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 153
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 152
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 151
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 151
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 151
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 151
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 151
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 151
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 150
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 149
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 148
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 148
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 146
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 146
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 144
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 144
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 143
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 142
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 142
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 141
Immune therapy of chronic myelogenous leukemia. 141
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 141
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 141
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 141
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 141
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 141
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 140
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 140
Analisi di polimorfismi in geni coinvolti nel ciclo dei folati come determinanti di suscettibilità a leucemia mieloide cronica. 139
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 139
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 139
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 137
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 137
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 137
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 137
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 136
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 136
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. 135
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 135
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 135
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? 134
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 134
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 134
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 133
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 133
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 132
Developing a new grading system of ocular surface disease after allogeneic hematopoietic stem cell transplantation (HSCT). 132
Totale 16.535
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.559
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010.943 0 0 0 0 1.507 1.415 1.752 1.837 1.998 925 614 895
2020/20217.853 1.421 571 165 320 252 421 172 436 714 432 467 2.482
2021/20229.676 1.049 266 732 966 913 622 191 620 358 759 1.637 1.563
2022/202310.280 1.243 1.576 584 1.343 677 817 370 535 1.621 236 810 468
2023/20242.533 152 424 151 247 209 602 152 134 87 153 99 123
2024/20254.407 284 1.609 770 687 1.057 0 0 0 0 0 0 0
Totale 54.376